ReviewCirculation. Cardiovascular interventions2019
Clopidogrel Pharmacogenetics.
Review in Circulation. Cardiovascular interventions, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06665919 (Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI), which is not on this map. Cited by 113 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Controlled Trial for Evaluating CYP2C19 Allele Genotype-guided Clopidogrel Treatment Outcomes in Real-world Practice After the ePCI
Who cites it
113 citing papers in PubMed, 5 syntheses or guidelines pooled it, 212 citations in OpenAlex.
- Interaction of CYP2C19 with the effect of clopidogrel in secondary prevention of major ischemic events: Systematic review and meta-analysis.International journal of stroke : official journal of the International Stroke Society · 2026Pooled it
- CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).British journal of clinical pharmacology · 2026Guideline
- Intravenous Tirofiban for Preventing Acute In-Stent Thrombosis in Emergent Carotid Artery Stenting: a Systematic Review and Meta-Analysis.Clinical neuroradiology · 2025Pooled it
- De-Escalation Dual Antiplatelet Therapy Prevail over Potent P2Y12 Inhibitor Monotherapy in Patients with Acute Coronary Syndrome Undergone Percutaneous Coronary Intervention: A Network Meta-Analysis.Reviews in cardiovascular medicine · 2022Pooled it
- Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2YJACC. Cardiovascular interventions · 2021Pooled it
- Machine Learning With Genetic and Clinical Data to Predict Ischemic Outcomes After PCI.Clinical and translational science · 2026Trial
- Cytochrome P450 2C19 Genotypes and Clopidogrel in Patients With Ischemic Stroke: A Nonrandomized Clinical Trial.JAMA network open · 2025Trial
- The Impact of CYP2C19 Genotype on the Platelet Reactivity Index (PRI) among Chronic Coronary Syndromes (CCS) Patients Undergoing Percutaneous Coronary Intervention (PCI): Affectability of Rapid Genetic Testing.Cardiovascular drugs and therapy · 2025Trial
- Safety and Efficacy of CYP2C19 Genotype-Guided Escalation of P2YCardiovascular drugs and therapy · 2024Trial
- Genetic-Guided Oral P2YJACC. Cardiovascular interventions · 2023Trial
- Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.Journal of the American Heart Association · 2022Trial
- ABCD-GENE Score and Clinical Outcomes Following Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.Journal of the American Heart Association · 2022Trial
- Pharmacokinetics, Bioequivalence and Safety Evaluation of Two Ticagrelor Tablets Under Fasting and Fed Conditions in Healthy Chinese Subjects.Drug design, development and therapy · 2021Trial
- Trial
- Patient-centred anti-platelet therapy following coronary artery bypass graft surgery.Journal of thrombosis and thrombolysis · 2026Review
- Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature.Clinical and translational science · 2026Review
- CYP450 Enzymes in Drug Metabolism and Personalized Medicine: A Narrative Review.Integrative medicine (Encinitas, Calif.) · 2026Article
- Cerebral Infarction: Epidemiology, Classification, Mechanisms, Diagnosis, and Management.MedComm · 2026Review
- Clopidogrel Dosing Scheme in Pediatric Cardiac Patients 0-24 Months Old Using P2YThe journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Successful management of the recurrent acute in-stent thrombosis despite optimal medical therapy: a case report and review of the literature.Journal of medical case reports · 2026Review
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 7 institutions in 3 countries.
Funding
Abstract
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide 19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-function alleles when treated with clopidogrel have significantly reduced clopidogrel active metabolite levels and high on-treatment platelet reactivity resulting in increased risk of major adverse cardiovascular events, especially after percutaneous coronary intervention. The Food and Drug Administration has issued a black box warning advising practitioners to consider alternative treatment in CYP2C19 poor metabolizers who might receive clopidogrel and to identify such patients by genotyping. However, routine clinical use of genotyping for CYP2C19 loss-of-function alleles in patients undergoing percutaneous coronary intervention is not recommended by clinical guidelines because of lack of prospective evidence. To address this critical gap, TAILOR-PCI (Tailored Antiplatelet Initiation to Lessen Outcomes due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention) is a large, pragmatic, randomized trial comparing point-of-care genotype-guided antiplatelet therapy with routine care to determine whether identifying CYP2C19 loss-of-function allele patients prospectively and prescribing alternative antiplatelet therapy is beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.